Medicaid, ACA costs will keep rising — and this insurer’s stock is tumbling

Elevance Health Inc. (ELV) shares tumbled 11.2% after the insurer significantly cut its 2025 adjusted EPS outlook to $30.00 from $34.15-$34.85 and missed Q2 profit expectations, attributing the revision to persistently rising costs in Medicaid and Affordable Care Act services. CEO Gail Boudreaux stated these elevated trends are expected to continue without a near-term recovery, impacting the company's benefit-expense ratio which rose to 88.9% and causing net income to fall 24.2%. This action, following similar warnings from peers like UnitedHealth, underscores broader industry concerns about healthcare cost inflation and suggests a full margin recovery may not occur until 2027 or 2028.

Analysis

Elevance Health's stock plummeted 11.2% after the company significantly reduced its 2025 adjusted EPS guidance to $30.00 from a prior range of $34.15-$34.85, citing persistent and industry-wide cost pressures from Medicaid and Affordable Care Act (ACA) services. This guidance cut is anchored in management's view that these elevated cost trends will continue without a near-term recovery. The company's second-quarter results underscored these challenges, with net income falling 24.2% and adjusted EPS of $8.84 missing the consensus of $8.91, marking its third profit miss in four quarters. A key indicator of this pressure, the benefit-expense ratio, deteriorated to 88.9% from 86.3% year-over-year. While total revenue grew 13.4% to $49.78 billion, beating forecasts, this top-line strength was insufficient to offset the severe margin compression. The issue is systemic, as evidenced by the concurrent stock declines in peers such as Centene, Molina, and UnitedHealth, and an analyst view from Mizuho suggests a full margin recovery may not occur until 2027 or 2028, signaling a prolonged period of difficulty for the sector.

Key Decisions for Investors

• Investors should re-evaluate exposure to Elevance Health, as the significant cut in 2025 EPS guidance and management's admission of persistent cost pressures signal a fundamental deterioration in the company's near-to-medium term earnings power.
• Exercise caution across the managed care sector, as the negative impact on peers like Centene, Molina, and UnitedHealth confirms that rising Medicaid and ACA costs are an industry-wide headwind, not an issue isolated to Elevance.
• Monitor future Medicaid rate cycle announcements and the company's benefit-expense ratio for signs of stabilization, given analyst commentary suggesting a full margin recovery might be delayed until 2027 or 2028.
• Prioritize profitability metrics over top-line growth, as the 13.4% revenue increase was completely overshadowed by the sharp decline in net income and the worsening benefit-expense ratio, which are the primary drivers of current investor sentiment.